Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

A booming gray market is turning kitchens into makeshift pharmacies as Americans chase cheaper alternatives to high-priced ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

In his new book, a former FDA commissioner unpacks the latest science on metabolism, weight loss, and how GLP-1 drugs ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Signs of advanced chronic pancreatitis include weight loss, a loss of appetite, jaundice, other symptoms associated with ...

Semaglutide is linked to a reduced risk for Alzheimer’s disease-related dementia in patients with diabetes vs other antidiabetic drugs, a new study suggests.

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...